Cancer stem-like properties in colorectal cancer cells with low proteasome activity

Clinical Cancer Research

Volumn 22, Issue 21, 2016, Pages 5277-5286

  Munakata, Koji ^a,b   Uemura, Mamoru ^a,c   Tanaka, Shinji ^d   Kawai, Kenji ^a   Kitahara, Tomohiro ^a   Miyo, Masaaki ^a   Kano, Yoshihiro ^e   Nishikawa, Shinpei ^e   Fukusumi, Takahito ^e   Takahashi, Yusuke ^a   Hata, Taishi ^a   Nishimura, Junichi ^a   Takemasa, Ichiro ^a   Mizushima, Tsunekazu ^a   Ikenaga, Masakazu ^f   Kato, Takeshi ^g   Murata, Kohei ^h   Carethers, John M ^b   Yamamoto, Hirofumi ^a   Doki, Yuichiro ^a   Mori, Masaki ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f OSAKA ROSAI HOSPITAL   (Japan)

^g KANSAI ROSAI HOSPITAL   (Japan)

^h Suita Municipal Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GREEN FLUORESCENT PROTEIN; ORNITHINE DECARBOXYLASE; OXALIPLATIN; PROTEASOME; REACTIVE OXYGEN METABOLITE; CARRIER PROTEIN; PLATINUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; BIOENGINEERING; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL ACTIVITY; CELL COUNT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL ISOLATION; CELL PROLIFERATION; COLON CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DLD1 CELL LINE; ENZYME ACTIVITY; EP300 INTERACTING INHIBITOR OF DIFFERENTIATION 3 GENE; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HCT116 CELL LINE; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IN VITRO STUDY; KM12SM CELL LINE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; SW480 CELL LINE; ANIMAL; COLORECTAL TUMOR; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; HCT 116 CELL LINE; METABOLISM; NONOBESE DIABETIC MOUSE; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; ORGANOPLATINUM COMPOUNDS; PROTEASOME ENDOPEPTIDASE COMPLEX; REACTIVE OXYGEN SPECIES; RESTING PHASE, CELL CYCLE;

EID: 84994588690     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1945     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009;138: 822-9.
3. Yang T, Rycaj K, Liu Z, Tang DG. Cancer stem cells: constantly evolving and functionally heterogeneous therapeutic targets. Cancer Res 2014;74: 2922-7.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
5. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
6. Gangopadhyay S, Nandy A, Hor P, Mukhopadhyay A. Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer 2013; 13:7-15.
7. Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlow B, Nestor M. Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells. PLoS One 2014;9:e94621.
8. Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010;6:603-15.
9. Margaritescu C, Pirici D, Cherciu I, Barbalan A, Cartana T, Saftoiu A. CD133/CD166/Ki-67 triple immunofluorescence assessment for putative cancer stem cells in colon carcinoma. J Gastrointestin Liver Dis 2014;23: 161-70.
10. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-7.
11. Oishi N, Yamashita T, Kaneko S. Molecular biology of liver cancer stem cells. Liver Cancer 2014;3:71-84.
12. Li L, Bhatia R. Stem cell quiescence. Clin Cancer Res 2011;17:4936-41.
13. Wyke SM, Russell ST, Tisdale MJ. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br J Cancer 2004;91:1742-50.
14. Zhang WG, Yu JP, Wu QM, Tong Q, Li SB, Wang XH, et al. Inhibitory effect of ubiquitin-proteasome pathway on proliferation of esophageal carcinoma cells. World J Gastroenterol 2004;10:2779-84.
15. Vlashi E, Kim K, Lagadec C, Donna LD, McDonald JT, Eghbali M, et al. In vivo imaging, tracking, and targeting of cancer stem cells. JNatl Cancer Inst 2009;101:350-9.
16. Pan J, Zhang Q, Wang Y, You M. 26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. PLoS One 2010;5: e13298.
17. Adikrisna R, Tanaka S, Muramatsu S, Aihara A, Ban D, Ochiai T, et al. Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. Gastroenterology 2012;143: 234-45.e7.
18. Della Donna L, Lagadec C, Pajonk F. Radioresistance of prostate cancer cells with low proteasome activity. Prostate 2012;72:868-74.
19. Muramatsu S, Tanaka S, Mogushi K, Adikrisna R, Aihara A, Ban D, et al. Visualization of stem cell features in human hepatocellular carcinoma reveals in vivo significance of tumor-host interaction and clinical course. Hepatology 2013;58:218-28.
20. Uemura M, Yamamoto H, Takemasa I, Mimori K, Hemmi H, Mizushima T, et al. Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells. Clin Cancer Res 2010;16:4636-46.
21. Takeyama H, Yamamoto H, Yamashita S, Wu X, Takahashi H, Nishimura J, et al. Decreased miR-340 expression in bone marrow is associated with liver metastasis of colorectal cancer. Mol Cancer Ther 2014;13:976-85.
22. Groll M, Schellenberg B, Bachmann AS, Archer CR, Huber R, Powell TK, et al. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature 2008;452:755-8.
23. Munakata K, Uemura M, Takemasa I, Ozaki M, Konno M, Nishimura J, et al. SCGB2A1 is a novel prognostic marker for colorectal cancer associated with chemoresistance and radioresistance. Int J Oncol 2014;44:1521-8.
24. Oh JY, Ko JH, Lee HJ, Yu JM, Choi H, Kim MK, et al. Mesenchymal stem/stromal cells inhibit the NLRP3 inflammasome by decreasing mitochondrial reactive oxygen species. Stem Cells 2014;32:1553-63.
25. Belloc F, Dumain P, Boisseau MR, Jalloustre C, Reiffers J, Bernard P, et al. A flow cytometric method using Hoechst 33342 and propidium iodide for simultaneous cell cycle analysis and apoptosis determination in unfixed cells. Cytometry 1994;17:59-65.
26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2005;2:416-22.
27. Tan SC, Carr CA, Yeoh KK, Schofield CJ, Davies KE, Clarke K. Identification of valid housekeeping genes for quantitative RT-PCR analysis of cardiosphere-derived cells preconditioned under hypoxia or with prolyl-4-hydroxylase inhibitors. Mol Biol Rep 2012;39:4857-67.
28. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009;27:1006-20.
29. Sasajima Y, Tanaka H, Miyake S, Yuasa Y. A novel EID family member, EID-3, inhibits differentiation and forms a homodimer or heterodimer with EID-2. Biochem Biophys Res Commun 2005;333:969-75.
30. Bavner A, Matthews J, Sanyal S, Gustafsson JA, Treuter E. EID3 is a novel EID family member and an inhibitor of CBP-dependent co-activation. Nucleic Acids Res 2005;33:3561-9.
31. Domae S, Nakamura Y, Nakamura Y, Uenaka A, Wada H, Nakata M, et al. Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity. Int J Cancer 2009;124:2347-52.
32. Neguembor MV, Xynos A, Onorati MC, Caccia R, Bortolanza S, Godio C, et al. FSHD muscular dystrophy region gene 1 binds Suv4-20h1 histone methyltransferase and impairs myogenesis. J Mol Cell Biol 2013;5: 294-307.
33. Mazumdar M, Glassman JR. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 2000;19: 113-32.
34. Mizuno H, Kitada K, Nakai K, Sarai A. Progno Scan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics 2009;2:18.
35. Cojoc M, Mabert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms. Semin Cancer Biol 2015;31:16-27.
36. Zeuner A, Todaro M, Stassi G, De Maria R. Colorectal cancer stem cells: from the crypt to the clinic. Cell Stem Cell 2014;15:692-705.
37. Tanase CP, Neagu AI, Necula LG, Mambet C, Enciu AM, Calenic B, et al. Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics. World J Gastroenterol 2014;20: 10790-801.
38. Muraro MG, Mele V, Daster S, Han J, Heberer M, Cesare Spagnoli G, et al. CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines. Stem Cells Transl Med 2012;1:592-603.
39. Wang C, Xie J, Guo J, Manning HC, Gore JC, Guo N. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep 2012;28:1301-8.
40. Chang TC, Yeh CT, Adebayo BO, Lin YC, Deng L, Rao YK, et al. 4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype. Toxicol Appl Pharmacol 2015;288: 258-68.
41. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011;17:313-9.
42. Pajonk F, McBride WH. The proteasome in cancer biology and treatment. Radiat Res 2001;156:447-59.
43. Vilchez D, Boyer L, Morantte I, Lutz M, Merkwirth C, Joyce D, et al. Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. Nature 2012;489:304-8.
44. Yin G, Alvero AB, Craveiro V, Holmberg JC, Fu HH, Montagna MK, et al. Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene 2013;32:39-49.
45. Inoue Y, Kusunoki M. Advances and directions in chemotherapy using implantable port systems for colorectal cancer: a historical review. Surg Today 2014;44:1406-14.
46. Hida J, Okuno K, Tokoro T. Distal dissection in total mesorectal excision, and preoperative chemoradiotherapy and lateral lymph node dissection for rectal cancer. Surg Today 2014;44:2227-42.
47. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010;16:3153-62.
48. Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov 2014;13:513-32.
49. Krausova M, Korinek V. Wnt signaling in adult intestinal stem cells and cancer. Cell Signal 2014;26:570-9.
50. Niess H, Camaj P, Renner A, Ischenko I, Zhao Y, Krebs S, et al. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis. Target Oncol 2015;10: 215-27.